aspirin has been researched along with acipimox in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Abouhajar, A; Alcock, L; Bigirumurame, T; Bradley, P; Brown, L; Campbell, I; Del Din, S; Faitg, J; Falkous, G; Gorman, GS; Lakey, R; McFarland, R; Newman, J; Rochester, L; Ryan, V; Smith, H; Steel, A; Stefanetti, RJ; Su, H; Taylor, RW; Thomas, NJP; Tuppen, H; Vincent, AE; Warren, C; Watson, G | 1 |
1 trial(s) available for aspirin and acipimox
| Article | Year |
|---|---|
Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy.
Topics: Adenosine Triphosphate; Adult; Aspirin; Child; Fatigue; Humans; Mitochondrial Myopathies; Muscular Diseases; Pyrazines; Quality of Life; Randomized Controlled Trials as Topic | 2022 |
1 other study(ies) available for aspirin and acipimox
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |